Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established therapies for diabetes and obesity, heart transplant recipients have been excluded from pivotal trials due to concerns regarding gastrointestinal intolerance, altered drug absorption, and possible interactions with immunosuppressants. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.